Effectiveness and safety of pidotimod in recurrent respiratory infections in children: a pilot study

Simple item page
dc.contributor.authorAcharya, T. C.en_US
dc.contributor.authorNivangune, Kundanen_US
dc.contributor.authorMuchhala, Snehal |Jain, |Rishien_US
dc.date.accessioned2020-09-24T07:45:04Z
dc.date.available2020-09-24T07:45:04Z
dc.date.issued2019-09
dc.description.abstractBackground: Recurrent respiratory infections (RRIs) are common in children especially in age 1 to 6 years. Pidotimod, an immunostimulant has been found to lower the recurrences of RRIs and improve the quality of life. The Objective of this study was to assess the efficacy and safety of pidotimod in children with recurrent respiratory infections (RRIs).Methods: In this single-centre, prospective, observational study, children aged 2 to 15 years diagnosed with RRIs were included. RRIs were defined as occurrence of 3 or more episodes of acute respiratory infections (ARIs) or more than 15 days of respiratory symptoms in the past 3 months. These children were treated with pidotimod in addition to standard care treatment. Treatment duration was two months and the follow-up continued for three months. Number of RRIs and severity of RRIs, antibiotic courses and rate of hospitalization before and after treatment were compared.Results: In total 25 children included in the study, mean age was 7.34'3.63 years. Among them, 68% were males. After treatment with pidotimod, there was significant reduction in mean number of ARI episodes (3.84'0.85 at baseline to 0.48'0.51 at follow-up, p<0.0001). Also, there was significant reduction in the duration of acute infectious episodes (p<0.0001), need of antibiotic courses (p<0.0001) and rates of hospitalization (p<0.0001). No safety concerns were identified and pidotimod was well tolerated.Conclusions: Addition of pidotimod to the standard treatment in children with RRIs significantly reduces the recurrence, duration of repeat infectious episodes, need of antibiotic treatments and future rates of hospitalizations. These findings support previous data.en_US
dc.identifier.affiliationsDepartment of Paediatrics, Acharya Children Hospital, New Jawahar Nagar, Kota, Rajasthan, Indiaen_US
dc.identifier.affiliationsDepartment of Medical Affair, Wockhardt Ltd., Wockhardt Towers, BKC, Mumbai, Maharashtra, Indiaen_US
dc.identifier.citationAcharya T. C., Nivangune Kundan, Muchhala Snehal |Jain |Rishi. Effectiveness and safety of pidotimod in recurrent respiratory infections in children: a pilot study. International Journal of Contemporary Pediatrics. 2019 Sep; 6(5): 2012-2015en_US
dc.identifier.issn2349-3283
dc.identifier.issn2349-3291
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/204224
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber5en_US
dc.relation.volume6en_US
dc.source.urihttps://dx.doi.org/10.18203/2349-3291.ijcp20193715en_US
dc.subjectChildrenen_US
dc.subjectImmunostimulanten_US
dc.subjectPidotimoden_US
dc.subjectRecurrent respiratory infectionsen_US
dc.titleEffectiveness and safety of pidotimod in recurrent respiratory infections in children: a pilot studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcp2019v6n5p2012.pdf
Size:
151.96 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Contemporary Pediatrics